nitro strength to someone who happens had Michael Davis and the heart transplant there is an ongoing clinical trial there is an ongoing prospective study looking at t1 mapping [Music] so most of the patients actually do not have follow-up so it shows you a few cases where some of the persons will follow-up had the same amount of scar some patients had less scar in a scale at all those are really the more negative cases most of the patients we’ve encountered I should do not get a my follow-up once the my occurred as good as I will so not diagnosed they do not come back for a subsequent exam usually when patients come in for all kind of America data saw a validation bigger than all the sequences that I showed you so we don’t pick and choose which one to run they learn all of them and then get results of each sequence T done mapping is something again that we don’t put clinically mainly because of the
Read next
GLP-1 Therapeutics Reshape Healthcare and Consumer Goods Sectors
Widespread adoption of metabolic medications triggers strategic pivots across pharmaceutical pipelines and food industries.
GLP-1 Agonist Manufacturing Supply Chains Struggle to Keep Pace with Global Demand
Pharmaceutical logistics providers face severe fill-finish bottlenecks as secondary suppliers work to expand sterile injectables capacity.
Sleep Research: Which Findings Actually Hold Up
A field with enormous popular attention and uneven evidence. Separating the well established from the widely repeated.
Regulatory Pathways Accelerate Adoption of Generative AI in Diagnostic Radiology
Health authorities have updated approval criteria for algorithmic diagnostic software, shortening validation timelines for clinical deployments.
GLP-1 Receptor Agonists Alter Commercial Food and Beverage Demand Patterns
Widespread adoption of anti-obesity medications is reshaping consumer purchasing behaviors, pushing consumer packaged goods companies to reformulate product…
GLP-1 Class Drugs Reshape Pharmaceuticals and Food Sector Valuations
Clinical trial expansions into cardiovascular and metabolic conditions spark revaluations across healthcare and consumer staple industries.